Trial Profile
A Multicenter, Randomized, Open-label Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With T2 DM With Inadequate Glycemic Control on Metformin.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary) ; Antihyperglycaemics; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 20 May 2009 Primary outcome changed from tolerability to, change from baseline in proportion of glycosylated haemoglobin as reported by ClinicalTrials.gov.
- 09 Apr 2009 New trial record